Role of the Chemokine Receptors CCR1, CCR2 and CCR4 in the Pathogenesis of Experimental Dengue Infection in Mice

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Guabiraba, Rodrigo ^a,b   Marques, Rafael Elias ^a   Besnard, Anne Gaëlle ^b   Fagundes, Caio T ^a   Souza, Danielle G ^a   Ryffel, Bernhard ^b   Teixeira, Mauro M ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITÉ D'ORLÉANS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR4; GAMMA INTERFERON; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TUMOR NECROSIS FACTOR ALPHA; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; LIGAND; PEROXIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DENGUE; DENGUE VIRUS 2; DISEASE ASSOCIATION; HEMOCONCENTRATION; INFLAMMATION; LETHALITY; LEUKOCYTE ACTIVATION; LIVER INJURY; LYMPHOCYTOPENIA; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; THROMBOCYTOPENIA; VIRUS LOAD; ANIMAL; C57BL MOUSE; DENGUE VIRUS; METABOLISM;

DENGUE VIRUS; FLAVIVIRUS; MUS;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; DENGUE; DENGUE VIRUS; INTERFERON-GAMMA; INTERLEUKIN-6; LIGANDS; MALE; MICE; MICE, INBRED C57BL; PEROXIDASE; RECEPTORS, CCR1; RECEPTORS, CCR2; RECEPTORS, CCR4;

EID: 78650843385     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015680     Document Type: Article

References (70)

1. Guzman MG, Kouri G (2002) Dengue: an update. Lancet Infect Dis 2: 33-42.
2. Mackenzie JS, Gubler DJ, Petersen LR (2004) Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 10: S98-109.
3. Kalayanarooj S, Vaughn DW, Nimmannitya S, Green S, Suntayakorn S, et al. (1997) Early clinical and laboratory indicators of acute dengue illness. J Infect Dis 176: 313-321.
4. Deen JL, Harris E, Wills B, Balmaseda A, Hammond SN, et al. (2006) The WHO dengue classification and case definitions: time for a reassessment. Lancet 368: 170-173.
5. Gibbons RV, Vaughn DW (2002) Dengue: an escalating problem. BMJ 324: 1563-1566.
6. Balmaseda A, Hammond SN, Perez L, Tellez Y, Saborio SI, et al. (2006) Serotype-specific differences in clinical manifestations of dengue. Am J Trop Med Hyg 74: 449-456.
7. Gubler DJ (1998) Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 11: 480-496.
8. Halstead SB, Streit TG, Lafontant JG, Putvatana R, Russell K, et al. (2001) Haiti: absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission. Am J Trop Med Hyg 65: 180-183.
9. Guzman MG, Kouri G, Valdes L, Bravo J, Vazquez S, et al. (2002) Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev Panam Salud Publica 11: 223-227.
10. Burke DS, Nisalak A, Johnson DE, Scott RM (1988) A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 38: 172-180.
11. Halstead SB, Nimmannitya S, Cohen SN (1970) Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med 42: 311-328.
12. Thein S, Aung MM, Shwe TN, Aye M, Zaw A, et al. (1997) Risk factors in dengue shock syndrome. Am J Trop Med Hyg 56: 566-572.
13. Clyde K, Kyle JL, Harris E (2006) Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. J Virol 80: 11418-11431.
14. Nisalak A, Endy TP, Nimmannitya S, Kalayanarooj S, Thisayakorn U, et al. (2003) Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999. Am J Trop Med Hyg 68: 191-202.
15. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, et al. (2000) Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 181: 2-9.
16. Martina BE, Koraka P, Osterhaus AD (2009) Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev 22: 564-581.
17. Balmaseda A, Saborio S, Tellez Y, Mercado JC, Perez L, et al. (2008) Evaluation of immunological markers in serum, filter-paper blood spots, and saliva for dengue diagnosis and epidemiological studies. J Clin Virol 43: 287-291.
18. Rodriguez-Madoz JR, Bernal-Rubio D, Kaminski D, Boyd K, Fernandez-Sesma A () Dengue virus inhibits the production of type I interferon in primary human dendritic cells. J Virol 84: 4845-4850.
19. Couvelard A, Marianneau P, Bedel C, Drouet MT, Vachon F, et al. (1999) Report of a fatal case of dengue infection with hepatitis: demonstration of dengue antigens in hepatocytes and liver apoptosis. Hum Pathol 30: 1106-1110.
20. Jessie K, Fong MY, Devi S, Lam SK, Wong KT (2004) Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization. J Infect Dis 189: 1411-1418.
21. Lee YR, Liu MT, Lei HY, Liu CC, Wu JM, et al. (2006) MCP-1, a highly expressed chemokine in dengue haemorrhagic fever/dengue shock syndrome patients, may cause permeability change, possibly through reduced tight junctions of vascular endothelium cells. J Gen Virol 87: 3623-3630.
22. Medin CL, Fitzgerald KA, Rothman AL (2005) Dengue virus nonstructural protein NS5 induces interleukin-8 transcription and secretion. J Virol 79: 11053-11061.
23. Navarro-Sanchez E, Despres P, Cedillo-Barron L (2005) Innate immune responses to dengue virus. Arch Med Res 36: 425-435.
24. Brown KL, Cosseau C, Gardy JL, Hancock RE (2007) Complexities of targeting innate immunity to treat infection. Trends Immunol 28: 260-266.
25. Speyer CL, Gao H, Rancilio NJ, Neff TA, Huffnagle GB, et al. (2004) Novel chemokine responsiveness and mobilization of neutrophils during sepsis. Am J Pathol 165: 2187-2196.
26. Rollins BJ (1997) Chemokines. Blood 90: 909-928.
27. Zlotnik A, Yoshie O (2000) Chemokines: a new classification system and their role in immunity. Immunity 12: 121-127.
28. Mantovani A (1999) Chemokines. Introduction and overview. Chem Immunol 72: 1-6.
29. Murphy PM (1994) The molecular biology of leukocyte chemoattractant receptors. Annu Rev Immunol 12: 593-633.
30. Baggiolini M (1998) Chemokines and leukocyte traffic. Nature 392: 565-568.
31. Locati M, Otero K, Schioppa T, Signorelli P, Perrier P, et al. (2002) The chemokine system: tuning and shaping by regulation of receptor expression and coupling in polarized responses. Allergy 57: 972-982.
32. Mantovani A (1999) The chemokine system: redundancy for robust outputs. Immunol Today 20: 254-257.
33. Glass WG, Rosenberg HF, Murphy PM (2003) Chemokine regulation of inflammation during acute viral infection. Curr Opin Allergy Clin Immunol 3: 467-473.
34. Horuk R, Proudfoot AE (2009) Drug discovery targeting the chemokine system-where are we? Front Biosci (Elite Ed) 1: 209-219.
35. Russo RC, Garcia CC, Teixeira MM. Anti-inflammatory drug development: Broad or specific chemokine receptor antagonists? Curr Opin Drug Discov Devel 13: 414-427.
36. Locati M, Murphy PM (1999) Chemokines and chemokine receptors: biology and clinical relevance in inflammation and AIDS. Annu Rev Med 50: 425-440.
37. Bozza FA, Cruz OG, Zagne SM, Azeredo EL, Nogueira RM, et al. (2008) Multiplex cytokine profile from dengue patients: MIP-1beta and IFN-gamma as predictive factors for severity. BMC Infect Dis 8: 86.
38. Spain-Santana TA, Marglin S, Ennis FA, Rothman AL (2001) MIP-1 alpha and MIP-1 beta induction by dengue virus. J Med Virol 65: 324-330.
39. Sierra B, Perez AB, Vogt K, Garcia G, Schmolke K, et al. MCP-1 and MIP-1alpha expression in a model resembling early immune response to dengue. Cytokine.
40. Conceicao TM, El-Bacha T, Villas-Boas CS, Coello G, Ramirez J, et al. Gene expression analysis during dengue virus infection in HepG2 cells reveals virus control of innate immune response. J Infect 60: 65-75.
41. Suksanpaisan L, Cabrera-Hernandez A, Smith DR (2007) Infection of human primary hepatocytes with dengue virus serotype 2. J Med Virol 79: 300-307.
42. Schnittler HJ, Feldmann H (2003) Viral hemorrhagic fever-a vascular disease? Thromb Haemost 89: 967-972.
43. Assuncao-Miranda I, Amaral FA, Bozza FA, Fagundes CT, Sousa LP, et al. Contribution of macrophage migration inhibitory factor to the pathogenesis of dengue virus infection. FASEB J 24: 218-228.
44. Atrasheuskaya A, Petzelbauer P, Fredeking TM, Ignatyev G (2003) Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection. FEMS Immunol Med Microbiol 35: 33-42.
45. Souza DG, Fagundes CT, Sousa LP, Amaral FA, Souza RS, et al. (2009) Essential role of platelet-activating factor receptor in the pathogenesis of Dengue virus infection. Proc Natl Acad Sci U S A 106: 14138-14143.
46. King CA, Anderson R, Marshall JS (2002) Dengue virus selectively induces human mast cell chemokine production. J Virol 76: 8408-8419.
47. Lin YL, Liu CC, Chuang JI, Lei HY, Yeh TM, et al. (2000) Involvement of oxidative stress, NF-IL-6, and RANTES expression in dengue-2-virus-infected human liver cells. Virology 276: 114-126.
48. Shresta S, Kyle JL, Robert Beatty P, Harris E (2004) Early activation of natural killer and B cells in response to primary dengue virus infection in A/J mice. Virology 319: 262-273.
49. Souza DG, Guabiraba R, Pinho V, Bristow A, Poole S, et al. (2003) IL-1-driven endogenous IL-10 production protects against the systemic and local acute inflammatory response following intestinal reperfusion injury. J Immunol 170: 4759-4766.
50. Binh PT, Matheus S, Huong VT, Deparis X, Marechal V (2009) Early clinical and biological features of severe clinical manifestations of dengue in Vietnamese adults. J Clin Virol 45: 276-280.
51. Green S, Rothman A (2006) Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis 19: 429-436.
52. Srikiatkhachorn A (2009) Plasma leakage in dengue haemorrhagic fever. Thromb Haemost 102: 1042-1049.
53. Srikiatkhachorn A, Krautrachue A, Ratanaprakarn W, Wongtapradit L, Nithipanya N, et al. (2007) Natural history of plasma leakage in dengue hemorrhagic fever: a serial ultrasonographic study. Pediatr Infect Dis J 26: 283-290; discussion 291-282.
54. Juffrie M, van Der Meer GM, Hack CE, Haasnoot K, Sutaryo, et al. (2000) Inflammatory mediators in dengue virus infection in children: interleukin-8 and its relationship to neutrophil degranulation. Infect Immun 68: 702-707.
55. Fink K, Ng C, Nkenfou C, Vasudevan SG, van Rooijen N, et al. (2009) Depletion of macrophages in mice results in higher dengue virus titers and highlights the role of macrophages for virus control. Eur J Immunol 39: 2809-2821.
56. Kyle JL, Balsitis SJ, Zhang L, Beatty PR, Harris E (2008) Antibodies play a greater role than immune cells in heterologous protection against secondary dengue virus infection in a mouse model. Virology 380: 296-303.
57. Shresta S, Kyle JL, Snider HM, Basavapatna M, Beatty PR, et al. (2004) Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T-and B-cell-dependent immunity are less critical. J Virol 78: 2701-2710.
58. Cardona AE, Sasse ME, Liu L, Cardona SM, Mizutani M, et al. (2008) Scavenging roles of chemokine receptors: chemokine receptor deficiency is associated with increased levels of ligand in circulation and tissues. Blood 112: 256-263.
59. Johnston B, Burns AR, Suematsu M, Issekutz TB, Woodman RC, et al. (1999) Chronic inflammation upregulates chemokine receptors and induces neutrophil migration to monocyte chemoattractant protein-1. J Clin Invest 103: 1269-1276.
60. Nouri-Aria KT, Wilson D, Francis JN, Jopling LA, Jacobson MR, et al. (2002) CCR4 in human allergen-induced late responses in the skin and lung. Eur J Immunol 32: 1933-1938.
61. Schuh JM, Power CA, Proudfoot AE, Kunkel SL, Lukacs NW, et al. (2002) Airway hyperresponsiveness, but not airway remodeling, is attenuated during chronic pulmonary allergic responses to Aspergillus in CCR4-/-mice. FASEB J 16: 1313-1315.
62. Vijayanand P, Durkin K, Hartmann G, Morjaria J, Seumois G, et al. Chemokine receptor 4 plays a key role in T cell recruitment into the airways of asthmatic patients. J Immunol 184: 4568-4574.
63. Yuan Q, Bromley SK, Means TK, Jones KJ, Hayashi F, et al. (2007) CCR4-dependent regulatory T cell function in inflammatory bowel disease. J Exp Med 204: 1327-1334.
64. Luster AD (2001) Antichemokine immunotherapy for allergic diseases. Curr Opin Allergy Clin Immunol 1: 561-567.
65. Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, et al. (2009) T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 113: 6392-6402.
66. Traeger T, Kessler W, Assfalg V, Cziupka K, Koerner P, et al. (2008) Detrimental role of CC chemokine receptor 4 in murine polymicrobial sepsis. Infect Immun 76: 5285-5293.
67. Chvatchko Y, Hoogewerf AJ, Meyer A, Alouani S, Juillard P, et al. (2000) A key role for CC chemokine receptor 4 in lipopolysaccharide-induced endotoxic shock. J Exp Med 191: 1755-1764.
68. Matsukawa A, Hogaboam CM, Lukacs NW, Lincoln PM, Evanoff HL, et al. (2000) Pivotal role of the CC chemokine, macrophage-derived chemokine, in the innate immune response. J Immunol 164: 5362-5368.
69. Kim CH, Johnston B, Butcher EC (2002) Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among V alpha 24(+)V beta 11(+) NKT cell subsets with distinct cytokine-producing capacity. Blood 100: 11-16.
70. Semmling V, Lukacs-Kornek V, Thaiss CA, Quast T, Hochheiser K, et al. Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs. Nat Immunol 11: 313-320.